Tags

Type your tag names separated by a space and hit enter

Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
J Pharm Pharm Sci. 2010; 13(3):378-90.JP

Abstract

PURPOSE

Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients.

METHODS

Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP), body weight, body mass index (BMI), glycated hemoglobin (HbA(₁c)), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (T(g)).

RESULTS

A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups, and a faster improvement of HbA(₁c), FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group.

CONCLUSIONS

Sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.

Authors+Show Affiliations

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P.le C. Golgi, 2-27100 Pavia, Italy. giuseppe.derosa@unipv.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

21092710

Citation

Derosa, Giuseppe, et al. "Effects of One Year Treatment of Sibutramine On Insulin Resistance Parameters in Type 2 Diabetic Patients." Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques, vol. 13, no. 3, 2010, pp. 378-90.
Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. J Pharm Pharm Sci. 2010;13(3):378-90.
Derosa, G., Maffioli, P., Ferrari, I., Palumbo, I., Randazzo, S., D'Angelo, A., & Cicero, A. F. (2010). Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques, 13(3), 378-90.
Derosa G, et al. Effects of One Year Treatment of Sibutramine On Insulin Resistance Parameters in Type 2 Diabetic Patients. J Pharm Pharm Sci. 2010;13(3):378-90. PubMed PMID: 21092710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. AU - Derosa,Giuseppe, AU - Maffioli,Pamela, AU - Ferrari,Ilaria, AU - Palumbo,Ilaria, AU - Randazzo,Sabrina, AU - D'Angelo,Angela, AU - Cicero,Arrigo F G, PY - 2010/11/25/entrez PY - 2010/11/26/pubmed PY - 2011/6/7/medline SP - 378 EP - 90 JF - Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques JO - J Pharm Pharm Sci VL - 13 IS - 3 N2 - PURPOSE: Comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients. METHODS: Two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP), body weight, body mass index (BMI), glycated hemoglobin (HbA(₁c)), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (T(g)). RESULTS: A faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups, and a faster improvement of HbA(₁c), FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. CONCLUSIONS: Sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight. SN - 1482-1826 UR - https://www.unboundmedicine.com/medline/citation/21092710/Effects_of_one_year_treatment_of_sibutramine_on_insulin_resistance_parameters_in_type_2_diabetic_patients_ L2 - http://ejournals.library.ualberta.ca/index.php/JPPS/article/viewFile/8262/7318 DB - PRIME DP - Unbound Medicine ER -